Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Follow-Up Questions
PRNAF 주식의 가격 성능은 어떻습니까?
PRNAF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Alterity Therapeutics Ltd의 주요 사업 주제나 업종은 무엇입니까?
Alterity Therapeutics Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
